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Abstract
Several biologic treatments are available in addition to intravenous also in subcutaneous form for treatment of
chronic diseases. Benefits of the subcutaneous application of drugs include self-administration by the patient,
shorter time of application process with less infusion related adverse events and consequently lower healthcare
costs. With appropriate education and support patients are able to administer their treatments at home. This leads
to improvement of quality of life, reduction of time needed to travel to the healthcare institution and consequently
also reduces costs also for the patient.
Over one million residents in the USA and 2.5 million in Europe are estimated to have inflammatory bowel disease
(IBD), with substantial costs for health care. These estimates do not factor in the ‘real’ price of IBD, which can
impede career aspirations, instil social stigma and impair quality of life in patients.
The Virtual Community Meeting, which offered an exchange of experience and opinions from healthcare
professionals who are active in treating IBD, and patients with this chronic disease, revealed in-depth arguments
and answers to some essential questions: which patients prefer subcutaneous over intravenous dosing; which
patients continue to favour intravenous infusions; what are the limitations regarding both applications; what is the
patient’s role in therapeutical decision-making and how does IBD affect the patient’s work, finances and quality of
life? The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from the
health-economic, scientific, and personal perspectives.
The meeting offered strong confirmation that most of the patients and healthcare professionals prefer
subcutaneous over intravenous drug administration but emphasise the management of risks associated with
treatment compliance. Patient education provided by the IBD team in this regard is mandatory. Quality of life of
patients is poorer during active disease, but the findings that it can improve over time, including as a result of
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home- or self-administration of biologics, may be encouraging for individuals with this chronic disease.
Keywords: Inflammatory bowel disease, Subcutaneous administration, Intravenous administration, Biotherapeutics,
Compliance, Quality of life
Introduction
Inflammatory bowel disease (IBD) is a chronic disease
which can cause progressive functional and structural
damage to the gastrointestinal tract. IBD comprises two
types: ulcerative colitis (UC) and Crohn’s disease (CD).
It was traditionally regarded as a disease of the wester-
nised nations, but in the twenty-first century, the epi-
demiology of IBD has been changing fast [1]. Within
Europe, the highest incidence and prevalence rates are
found in Scandinavia and the United Kingdom while the
diseases, according to the latest data available, remain
rare in Eastern Europe. However, the occurrence of IBD
is a dynamic process as demonstrated by the increasing
incidence rates being reported from previously low inci-
dence areas, including Eastern Europe. The incidence of
CD in Europe ranges from 0.5 to 10.6 cases per 100,000
person-years while the estimates for UC range from 0.9
to 24.3 per 100,000 person-years [2].
Over the last decade, biologics have gained an im-
portant place in the treatment of moderate to severe
IBD, and many randomised control trials have evalu-
ated their efficacy. Currently, monoclonal antibodies
against tumour necrosis factor-alpha (infliximab, ada-
limumab, certolizumab, and golimumab), integrins
(vedolizumab and natalizumab*), and interleukin
(IL)-12 and IL-23 antagonists (ustekinumab) are ap-
proved for use in IBD [3].
Subcutaneous delivery of biotherapeutics has become
a valuable alternative to intravenous administration
across many disease areas. Subcutaneous administration
has been proven to be effective, safe, well-tolerated, gen-
erally preferred by patients and healthcare providers,
and it results in reduced drug delivery-related healthcare
costs and resource use [3]. The aim of this report is to
present the results from the Virtual Community Meeting
which took place from January 21 to February 4, 2021
and contributed relevant insights regarding intravenous
and subcutaneous drug administration from healthcare
professionals located in nine Central and Eastern Euro-
pean Countries (Bulgaria, Croatia, Estonia, Hungary,
Latvia, Lithuania, Romania, Serbia, Slovenia) and patient
organisation representatives from six Central and East-
ern European Countries (Bulgaria, Croatia, Hungary,
Romania, Serbia, Slovenia). As IBD is a chronic disease,
involving patients in the treatment decision-making
process is very important.
Intravenous versus subcutaneous drug
administration: an expert’s perspective
Because subcutaneous administration allows self-
injections outside the hospital setting, it reduces patient
dependency on hospital facilities and results in reduced
drug delivery-related healthcare costs and resource use.
It is also less time-consuming and minimises the dis-
comfort associated with intravenous infusion. Adverse
events associated with subcutaneous administration may
occur due to inappropriate storage of the drug at home
or potential local allergic manifestations. According to
the Virtual Community Meeting, the COVID-19 pan-
demic did not influence the administration of biologics,
but it is evidently easier to manage subcutaneous formu-
lation during the pandemic.
The main drivers for switching from intravenous to
subcutaneous administration of biologics can be divided
into three groups: medical considerations (disease im-
provement/stabilisation, facility decongestion, patient in-
volvement in management), patient considerations
(preference for a more comfortable and easy-to-deliver
formula, self-administration, a more flexible schedule, a
limited dependence on medical facilities and staff), and
administrative considerations involving costs and, in
some countries, insurance reimbursement.
Participating experts agreed that almost all patients
would be suitable for a subcutaneous formulation as
maintenance therapy. There are, however, concerns as-
sociated with self-administration in patients with a low
educational level, and with non-compliant patients.
Some patients find it difficult to overcome their fear of
self-injecting. Some patients find it too frequent to ad-
minister an injection every week or every second week,
while the intravenous infusion is usually needed just
once in 8 weeks. Many patients also feel safer if they re-
ceive the medication intravenously in a hospital because
they trust the medical staff and they may feel that their
disease is more under control if the treatment process is
left to the professionals. To overcome these psycho-
logical and objective barriers, extended patient education
and open communication in this regard is mandatory.
Among the patients suitable for subcutaneous admin-
istration of biologics, experts assessed the proportion of
those suitable for injector pen/auto-injector pen versus
pre-filled syringe: the majority agreed that 80 to 95% of
their patients prefer injector pen/auto-injector pen as a
delivery method. The importance of patients’ role in the
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choice of biologic formulation is presented in are pre-
sented in Fig. 1.
Compliance/adherence risks and additional
medical support
Patient education provided by the IBD team (a nurse
and a physician) is most important for correct self-
injecting practice. Patients must be trained, and their
skills assessed after the training. Data regarding the pa-
tient’s experience must be collected during the treat-
ment and reasonable control of their skills must also be
performed. Additional tools that could help the patients
are, for example, training kits, leaflets, and simple video
instructions. During the COVID-19 pandemic,
mandatory social distancing and a lack of effective treat-
ments have made telemedicine the safest interactive sys-
tem between patients, both infected and uninfected, and
clinicians.
Patients support programmes (such as IBD nurse sup-
port of patients and calls to remind them to take their
medication) could be very useful for IBD patients, but
they are underdeveloped or non-existent in most of the
countries involved in the Virtual Community. The use of
mobile applications to monitor/manage the disease is
not common in IBD practices, although researchers and
practitioners are developing these tools to provide better
monitoring of their patients and to improve compliance.
The main compliance/adherence risks are incorrect ad-
ministration of injections, missed doses, and inappropri-
ate storage, which raises the need for a steady
temperature control.
Age, education, and history of the disease
Taking into account all the circumstances, HCPs dis-
cussed which patients would be more suitable for
intravenous and which for subcutaneous application. Pa-
tients with IBD who have a long history of disease, pa-
tients with more severe and active disease, and patients
with a history of previous unsuccessful treatment with
other biologics are more suitable candidates for intra-
venous medication. The same applies to less educated
patients and patients with a fear of self-injections. On
the other hand, young patients who have a short history
of disease which is under control after induction therapy
and who have no reservations about self-injections are
potential candidates for maintenance subcutaneous ap-
plication. These are mainly educated, active people. The
participants of the meeting had already accumulated a
considerable amount of experience with vedolizumab
intravenous therapy. Most of them would initiate a
maintenance regimen with subcutaneous administration
of the drug as soon as it is available on the market if the
disease is well controlled – when remission is achieved.
The main factors impacting the choice of subcutane-
ous application are presented in Fig. 2.
Intravenous versus subcutaneous drug
administration: a patient’s perspective
At the Virtual Community Meeting, six patient repre-
sentatives all expressed preference for subcutaneous ad-
ministration and presented a long list of positive
experiences. It is less time-consuming, and it takes less
effort and time absent from work when self-
administration is performed at home, they reported.
Subcutaneous application systems are designed with
smaller needle sizes, which may decrease pain during
administration. Furthermore, administration at home
reduces the risk of exposure to hospital-acquired in-
fections. Subcutaneous application is expected to im-
prove patient quality of life and provide support to
Fig. 1 Scale of importance of patients’ role in the choice of biologic formulation
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patients who live far from a hospital or have difficul-
ties travelling and parking in the vicinity of the hos-
pital. This can contribute to a lower financial burden,
taking into consideration that IBD patients often have
part-time jobs or are unemployed. Nevertheless, visit-
ing the hospital is time-consuming and is often a bur-
den for another family member or friend who
accompanies the patient.
Patients – as with health care professionals – are
convinced that the subcutaneous route of application
is more suitable for younger, employed patients, while
the intravenous route is more appropriate for older
patients, especially those who refuse to inject them-
selves and feel safer when receiving therapy in a hos-
pital environment.
Convenience of choice and less frequent
administrations
Which kind of drug administration would patients pre-
fer? Oral - if this is not available, then subcutaneous, as
reported by the patient representatives. The most im-
portant decisive factors are less frequent drug adminis-
trations and the convenience of choice. As IBD is a
chronic disease, involving patients in the decision-
making process is very important. The patient should
know the benefits, risks, and adverse reactions associated
with the treatment. The decision on the most appropri-
ate biological therapy should be made by the patient and
the doctor together. The main reasons for patinets to
prefer subcutaneous application are presented in Fig. 3.
Quality of life and the patient’s role
Numerous studies have shown that health-related quality
of life is impaired in patients living with IBD as com-
pared with the general population. While disease activity
and severity are an important driver of physical and
mental health-related quality of life, patients may experi-
ence psychological distress even during clinical remis-
sion. Living with IBD can impact employment, family
planning, and personal milestones. Furthermore, the
Fig. 2 Factors impacting favorable choice of subcutaneous application
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impact of IBD extends to the patient influencing the
quality of the lives of those around them, including their
caregivers [4].
The vision of IBD patient societies is to provide assist-
ance, patient counselling, education, and verified infor-
mation and knowledge about the disease. It is not
enough that only the members of the IBD society are ed-
ucated. As the disease affects all aspects of the patient’s
life, it is important that the professional and the general
public are well-informed, too, and that they can recog-
nise the patient’s needs and make the appropriate adjust-
ments for their well-being. Recently, patient societies
have become involved in scientific and therapeutic activ-
ism. The concept of the ‘expert patient’ or the ‘expert of
experience’ has developed. Many patient organisations
have developed processes and methodologies to ensure
that their members are fully prepared to become in-
volved in areas such as research and clinical trials.
Conclusions
The Virtual Community Meeting delivered some inter-
esting findings about the treatment of IBD based on the
view of healthcare professionals and patient organisation
representatives from Bulgaria, Croatia, Estonia, Hungary,
Latvia, Lithuania, Romania, Serbia, and Slovenia. Prefer-
ence studies and practical experience have revealed that
most of the patients and healthcare professionals prefer
subcutaneous over intravenous drug administration.
Among the patients suitable for subcutaneous adminis-
tration of biologics, 80 to 95% prefer injector pen/auto-
injector pen as a delivery method. Patient education pro-
vided by the IBD team (a nurse and a physician) is most
important for correct self-injecting practice and manage-
ment of the risks associated with treatment compliance
(wrong injection applications, missed doses, inappropri-
ate storage of the drug). As IBD is a chronic disease, in-
volving patients in the therapy decision-making process
is very important. Patient education and their involve-
ment in the decision-making process increases their re-
sponsibility and treatment compliance, which have an
important impact on the efficiency of the disease
management.
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